Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine
NCT ID: NCT01289938
Last Updated: 2016-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
49 participants
INTERVENTIONAL
2009-07-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers
NCT03809234
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
NCT02155309
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
NCT00139893
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
NCT04226170
Metoclopramide for Migraine: A Dose Finding Study
NCT00682734
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Metoclopramide
Metoclopramide treatment
Metoclopramide
10 mg i.v. metoclopramide once
Diphenhydramine
Diphenhydramine treatment
Diphenhydramine
Diphenhydramine 50 mg oral once
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diphenhydramine
Diphenhydramine 50 mg oral once
Metoclopramide
10 mg i.v. metoclopramide once
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasians
* Healthy volunteers
Exclusion Criteria
* Drug allergy
* Acute and chronic diseases
* Taking medication
* Abuse of drugs, alcohol etc.
* Smoker
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Matthias Schwab
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthias Schwab
Prof. M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias Schwab, MD
Role: PRINCIPAL_INVESTIGATOR
UKT
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abteilung Klinische Pharmakologie, UKT Tübingen
Tübingen, Baden-Wurttemberg, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta. 2007 Mar;1770(3):489-94. doi: 10.1016/j.bbagen.2006.09.019. Epub 2006 Oct 4.
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007 Nov 20;25(33):5187-93. doi: 10.1200/JCO.2007.12.2705.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-003778-16
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
IKP231
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.